Mural Oncology Plc (MURA) Return on Equity ROE from the third quarter 2025 to third quarter 2024 and annually, average high and low, overall ranking from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Mural Oncology Plc  (NASDAQ: MURA)

Mural Oncology Plc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Mural Oncology Plc in the third quarter 2025?
Mural Oncology Plc recorded a cumulative net loss of $-119 million during 12 months ending in the third quarter 2025, resulting in a negative return on equity (ROE) of -131.47%.

Within the Major Pharmaceutical Preparations industry 273 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2025 from 3086 to 3367.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Equity Change -68.31 % -71.27 % -54.08 % -46.74 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -119 -147 -131 -129 -154
Return On Equity (TTM) -131.47 % -122.29 % -83.39 % -68.16 % -70.1 %
MURA's Total Ranking # 3367 # 3086 # 2619 # 3144 # 3369
Equity (TTM) in Millions 55 59 108 141 174
Seq. Equity Change -6.12 % -45.51 % -23.21 % -19.32 % -14.88 %
Seq. Net Income Change - - - - -

Back to MURA Management Effectiveness >> MURA's 5 Years Annual ROE >> Compare MURA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 274
Sector # 585
Overall # 3367

Return On Equity Statistics
High Average Low
-68.16 %
-103.89 %
-131.47 %
(Dec 31 2024)   (Sep 30 2025)



  News about Mural Oncology Plc Return on Equity ROE

Mural Oncology Pioneers Innovative Therapies and Employee Incentives Amidst Tumultuous Market Conditions

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)In a strategic move reflecting its commitment to both innovation and talent acquisition, Mural Oncology plc (Nasdaq: MURA), a clinical-stage company specializing in immuno-oncology, recently reported significant employment initiatives. On December 2, 2024, the company announced the granting of non-statutory stock options and restricted stock units to four newly hired employees, amounting to 26,300 and 13,200 ordinary shares, respectively. These grants are in accordance with the company s 2024 Inducement Stock Option and Incentive Plan, adhering to Nasdaq Listing Rule 5635(c)(4). This initiative is designed to attract skilled individuals to further Mural’s mission of developing groundbreaking engineered cytokine therapies to address unmet medical needs in cancer care.This announcement directly follows Mural Oncology’s earlier disclosure of promising clinical findings from its ARTISTRY-1 clinical trial, which evaluates its lead engineered fusion protein, Nemvaleukin. This protein has shown encouraging therapeutic activity against advanced solid tumors, offering a glimmer of hope for patients battling heavily pretreated conditions, notably platinum-resistant ovarian cancer (PROC). Published in the Journal for ImmunoTherapy of Cancer, the trial results underscore Nemvaleukin s favorable safety profile and durable responses when used as a standalone treatment or in combination therapies.



MURA Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (FY 2012)
(Dec. 29, 2012)

Total Equity in Millions 141 264 0 0 0
Y / Y Equity Change -46.74 % - - - -
Net Income in Millions -129 -207 964 0 0
Y / Y Net Income Change - - - - -
Return On Equity -91.47 % -78.63 % - - -

Back to MURA Management Effectiveness >> MURA's 5 Years Annual ROE >> Compare MURA ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
MURA's' Return on Equity at Yahoo Finance
MURA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for MURA's Competitors
Subscribers only: Roe for Mural Oncology Plc's Suppliers
Subscribers only: Return On Equity for MURA's Customers




Companies with similar Return On Equity at Sep 30 2025, within Healthcare Sector ROE

Date modified: 2026-08-29T17:49:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.